摘要
Abstract
OBJECTIVE:To evaluate therapeutic efficacy and safety of sitagliptin combined with other glucose-lowering drugs in the treatment of type 2 diabetes.METHODS:Retrieved from Cochrane Library,PubMed,EMbase and CNKI,randomized controlled trials (RCT) about sitagliptin combined with other glucose-lowering drugs in the treatment of type 2 diabetes were collected.The quality of included literatures was evaluated according to the Cochrane Collaboration system review,and then Meta-analysis was performed using Rev Man 5.1 software.RESULTS:A total of 17 RCT were included,involving 3 643 patients.Results of meta-analysis showed that HbA1c [WMD=-0.23,95％CI(-0.40,-0.06),P＜0.05],FPG [WMD=-0.70,95％CI(-1.21,-0.18),P＜0.05] and body weight index [WMD=-1.67,95％ CI(-2.02,-1.32),P＜0.05] of sitagliptin group were better than those of control group,there was statistical significance.The number of hypoglycemia events in sitagliptin group was significantly lower than in control group,there was statistical significance [RR =0.36,95 ％ CI (0.16,0.82),P＜ 0.05].CONCLUSIONS:Sitagliptin can effectively control the blood glucose in patients with type 2 diabetes with sound safety.But its long-term efficacy and safety still need to be confirmed by performing more high quality,large-scale RCT with long-term following-up.关键词
西格列汀/2型糖尿病/Meta分析/系统评价Key words
Sitagliptin/Type 2 diabetes/Meta-analysis/Systematic review分类
医药卫生
